Venobiotech Selected for '2026 Global Corporate Collaboration Program'... Accelerates Pan-KRAS Drug Commercialization

Venobiotech, a new drug development specialist and an affiliate of KOSDAQ-listed Benoty&Ar, has been selected for a collaborative program jointly promoted by the government and a global corporation, accelerating its global commercialization of AI-based anti-cancer drugs.

On May 28, Venobiotech announced that it was finally selected as a participating company in the 'DAONDA' program, a collaboration with Dassault Systèmes under the '2026 Global Corporate Collaboration Program' supervised by the Ministry of SMEs and Startups and the Korea Startup Promotion Agency.

The DAONDA program is a public-private cooperative R&D initiative in which the government and global corporations work together to support domestic promising startups in research and development and overseas market expansion. Venobiotech plans to use this program as a springboard to actively pursue the global commercialization of its independently developed physics law-based AI platform, 'PHY-AI', which led to the discovery of the Pan-KRAS inhibitor 'BBRP11031'.

Currently under development, BBRP11031 is an innovative new drug candidate that targets all KRAS mutations, which play a critical role in cancer cell growth. The company explained that the high binding energy calculated by its physics law-based AI and the results of precise molecular simulations received positive evaluations during the selection process, further enhancing the competitiveness of its pipeline.

In particular, BBRP11031 is drawing attention as a next-generation anti-cancer therapy because it is a Pan-KRAS series drug candidate aimed at all KRAS mutations. The company aims to strengthen its overseas market penetration by combining its AI-based drug design capabilities with a global collaboration framework.

Executive Vice President Inhyeon Lee stated, "This selection once again proves that Venobiotech's AI-based new drug development technology is at a global level," adding, "By actively utilizing the collaborative system with global corporations, we will maximize the value of our core pipeline, including BBRP11031, and grow into a globally competitive biotech company."

Meanwhile, Venobiotech is also smoothly conducting Phase 1 clinical trials for 'BBRP11001', a treatment for macular degeneration. The company is actively working to expand its new pipeline and build global partnerships based on its AI platform technology.

This selection for the Global Corporate Collaboration Program is seen as a milestone that demonstrates Venobiotech is accelerating its efforts to enter the global anticancer drug market, leveraging its capabilities in AI-based innovative drug development.

This content was produced with the assistance of AI translation services.